“We are the only state really left in the country that is requiring extracts in their products.”
By Robin Opsahl, Iowa Capital Dispatch
Iowa medical cannabis manufacturers told Iowa lawmakers Tuesday that allowing the sale of raw cannabis flowers in the state’s medical cannabidiol (CBD) program would reduce costs for patients.
But representatives of state agencies who spoke at a House subcommittee meeting said the change could cause problems for law enforcement and safety on state roads.
Iowa lawmakers advanced House Study Bill 532 through a three-member subcommittee Tuesday. The bill would change Iowa’s definition of “medical cannabidiol” to include forms of oral, topical and inhalable cannabis—including raw cannabis flower.
Dane Schumann, a lobbyist with MedPharm Iowa, one of the firms licensed to manufacture medical marijuana in the state, said the current Iowa Code requires medical cannabis products to be extracts. That means manufacturers grow marijuana plants, extract the active compounds known as CBD and THC from those crops and create a new product to sell for use through the medical cannabis program.
This process is costly, and Schumann said MedPharm was advocating for a change in language to allow for other versions of cannabis because it would result in
Read full article on Marijuana Moment